(Q36128232)

12 August 2017

1 reference

title

The graft-versus-lymphoma effect: clinical review and future opportunities (English)

1 reference

12 August 2017

Butcher BW

1

1 reference

12 August 2017

Collins RH Jr

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Bone Marrow Transplantation

12 August 2017

published in

1 reference

12 August 2017

volume

36

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

1-17

1 reference

Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Successful treatment with reduced-intensity stem cell transplantation in a case of relapsed refractory central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Continuous complete clinical and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Mini-review: overcoming tumor-intrinsic resistance to immune effector function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Part II: Vaccines for haematological malignant disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Cancer stem cell biology: from leukemia to solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Graft versus Burkitt's lymphoma effect after allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Nonmyeloablative stem cell transplantation for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

How does bone-marrow transplantation cure leukaemia?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

1 reference

7 January 2021

Mini-allografts: ongoing trials in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

The graft-versus-lymphoma effect: fact, fiction, or opportunity?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Second allogeneic transplantation after failure of first autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Long-term results of blood and marrow transplantation for Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705008

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705008

1 reference

12 August 2017

1 reference